Amneal Pharmaceuticals, Inc. (AMRX): Capital Expenditures
$70.06M
Year ended 2025-12-31
$72.94M
Trailing 12 months to 2026-06-30
+14.7%
3-year compound annual growth
+4.4%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $70.06M | +34.9% | 2026-02-27, From 2025-01-01 |
| 2024-12-31 | $51.92M | +20.1% | 2026-02-27, From 2024-01-01 |
| 2023-12-31 | $43.22M | -6.9% | 2026-02-27, From 2023-01-01 |
| 2022-12-31 | $46.41M | -2.8% | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | $47.73M | -15.4% | 2024-03-14, From 2021-01-01 |
| 2020-12-31 | $56.45M | +19.6% | 2023-03-03, From 2020-01-01 |
| 2019-12-31 | $47.18M | -43.2% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $83.09M | -12.3% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $94.77M | -22.8% | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $122.76M | n/a | 2019-03-01, From 2016-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | 2025-12-31 | $70.06M | +34.9% |
| United Therapeutics Corp (UTHR) | 2025-12-31 | $520.50M | +111.2% |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $103.04M | +20.6% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $58.70M | +71.2% |
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | $101.97M | -25.5% |
| Perrigo Co PLC (PRGO) | 2025-12-31 | $93.40M | -21.0% |
| Jazz Pharmaceuticals plc (JAZZ) | 2025-12-31 | $58.75M | +54.3% |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $276.00M | +87.8% |
| PTC Therapeutics, Inc. (PTCT) | 2025-12-31 | $8.86M | +36.3% |
Compare AMRX, UTHR, BMRN, ALNY side by side · Screen every company in Pharmaceutical Preparations ↗